Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trilogy International Partners Inc T.TRL.WT.A


Primary Symbol: V.TRL.H

Trilogy International Partners Inc. operates through its subsidiary Trilogy International Partners LLC (Trilogy LLC). Prior to the disposal of its New Zealand and Bolivia operations, Trilogy LLC was a provider of wireless voice and data communications services including local, international long distance and roaming services. Trilogy LLC also provided fixed broadband communications services to residential and enterprise customers in New Zealand and Bolivia. The Company had two reportable segments identified by their geographic regions, New Zealand and Bolivia. Two Degrees Mobile Limited (2degrees) operated in New Zealand and Empresa de Telecomunicaciones NuevaTel (PCS de Bolivia), S.A. (NuevaTel) operated in Bolivia. Both these segments provided a variety of wireless voice and data communications services, including local, international long distance and roaming services. The services were provided to subscribers on both a postpaid and prepaid basis.


TSXV:TRL.H - Post by User

Post by LTOWNERon Aug 08, 2012 9:08am
294 Views
Post# 20193219

Q4 Partnership?

Q4 Partnership?

Both management and the RBC analyst appear to assume a partnership "event" will be announced in Q4.  I believe the word "products" (i.e. plural) were mentioned in conjunction with this partnering event, which may or may not mean Compleo and Tefina are to be linked.  Soon after the 'event', development of an asthma product is to begin.  Management calls past quarter "exciting and productive" in terms of moving toward an NDA to the FDA for Compleo.  

 

The market for Testosterone continues to grow and is now projected to be US $5 Billion by 2017.  It is one of the fastest growing markets in the US.  Lilly is currently "creating noise" to influence this growth in the marketplace and Androgel is now Abbott's 3rd largest product.

Bullboard Posts